|
|
|
|
|
|
|
|
|
|
|
31.07.26 - 10:33
|
Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results (Business Wire)
|
|
|
Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit revised upward
Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026.
“Daiichi Sankyo delivered strong revenue growth in the first quarter of fiscal year 2026 as we began execution of our new Five-Year Business Plan,” said Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo. “Three new U.S. approvals for Enhertu and Datroway were received in a single week in May, underscoring the continued strength of our portfolio where we anticipate delivering more than 20 new indications across five medicines by 2030. These results reinforce the durability of our growth trajectory and support our outlook for fiscal 2026 and beyond.”
Q1 FY2026 Results
Global revenue increased 21.1% year-over-ye...
|
|
|
|
|
31.07.26 - 08:54
|
Datroway approved in EU for TNBC (Cision)
|
|
|
31 July 2026
Datroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy
Approval based on TROPION-Breast02 Phase III trial results where AstraZeneca and Daiichi Sankyo's Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival
Datroway now approved for two breast cancer indications in the EU
AstraZeneca and Daiichi Sankyo's Datroway (datopotamab...
|
|
|
31.07.26 - 07:54
|
Otsuka Holdings Co., Ltd. H1 Income Climbs (AFX)
|
|
|
TOKYO (dpa-AFX) - Otsuka Holdings Co., Ltd. (OTSKF) announced a profit for its first half that Increased, from last yearThe company's earnings totaled JPY215.612 billion, or JPY409.07 per share. T......
|
|
|
31.07.26 - 07:54
|
HOYA Corporation Q1 Income Advances (AFX)
|
|
|
TOKYO (dpa-AFX) - HOYA Corporation (HYB.F) released a profit for its first quarter that Increased, from the same period last yearThe company's bottom line came in at JPY65.791 billion, or JPY196.5......
|
|
|
|
|
|
|
30.07.26 - 22:06
|
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda (GlobeNewswire EN)
|
|
|
LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it will receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MDS clinical trial. ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of elritercept versus epoetin alfa for the treatment of anemia due to very low, low, or intermediate risk myelodysplastic syndromes (“MDS”)....
|
|
|
|
|
|
|
|
|
|
|
30.07.26 - 08:39
|
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track (Business Wire)
|
|
|
Solid first quarter performance broadly in line with guidance, underpinned by resilient demand across core in-line brands
Commercial execution and late-stage pipeline investments on schedule, including first approval for ORZEYFULTM (oveporexton) in China, setting the foundation for next wave of medicines
No change to FY2026 full-year forecast and management guidance
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined execution and operational momentum. Takeda leveraged the resilient performance of its core in-line portfolio to support its long-term strategy, advancing commercial launch preparations and driving critical R&D pipeline milestones. With a clear operational trajectory established in the first quarter and under a new operating model, Takeda remains on track to deliver its strategic and financial commitments for the fiscal year.
FY2026 First Quarter Highl...
|
|
|
|
|
|
|
29.07.26 - 10:48
|
Eisai and CORE Biomedicine agree on global licence for oncology pipeline (PBR)
|
|
|
The deal grants CORE Biomedicine rights to develop and commercialise a portfolio of cancer therapies originally discovered by Eisai and its affiliates. The licensed assets focus on targeting
The post Eisai and CORE Biomedicine agree on global licence for oncology pipeline appeared first on Pharmaceutical Business review....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
